Key result
Adjuvant chemotherapy significantly improved 5-year disease-free survival compared to no chemotherapy (75% vs 54%, P=0.037) in patients with high-grade extremity soft-tissue sarcomas.
Why the study?
Does adjuvant chemotherapy improve survival in patients with high-grade soft-tissue sarcomas of the extremity?
Population
Patients with high-grade soft-tissue sarcomas of the extremity (n=88 in the subsequent trial)
Comparison
Adjuvant chemotherapy vs No chemotherapy or high-dose chemotherapy regimen
Design
RCT, randomized
Follow-up
7.1 years (initial trial) and 4.4 years (subsequent trial)
Authors
Loading...
Adjuvant chemo may benefit high-grade extremity sarcomas; leaves open confirmation in modern randomized trials.
RCT
Does adjuvant chemotherapy improve survival in patients with high-grade soft-tissue sarcomas of the extremity?
Absolute Event Rate: 75% vs 54%
p-value: p=0.037
Adjuvant chemotherapy improves disease-free survival in high-grade extremity soft-tissue sarcomas, and a reduced-dose regimen maintains efficacy while avoiding doxorubicin-induced cardiomyopathy.
Chang et al. (1988) conducted an RCT in High-grade soft-tissue sarcomas of the extremity. Adjuvant chemotherapy (doxorubicin, cyclophosphamide, and methotrexate) vs. No chemotherapy was evaluated on 5-year disease-free survival (p=0.037). Adjuvant chemotherapy significantly improved 5-year disease-free survival compared to no chemotherapy (75% vs 54%, P=0.037) in patients with high-grade extremity soft-tissue sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: